INFORMATION DISCLOSURE STATEMENT Form PTO-1449 (Use several sheets if necessary)	ATTY. DOCKET NO. 065477-0030	SERIAL NO. 10/531,366
	APPLICANT Per Sonne Holm	
	FILING DATE 04-14-2005	GROUP 1636

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE

U.S. PATENT APPLICATION PUBLICATIONS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
							YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
/D.G./		Hongtao Zhang et al., *Therapeutic Monoclonal Antibodies for the ErbB Family of Receptor Tyrosine Kinases,* Cancer Biology & Therapy, Vol. 2 Issue 4 Suppl.1, S122-6 (2003)
/D.G./		Thijn R. Brummelkamp, et al., *A System for Stable Expression of Short Interfering RNAs in Mammalian Cells*, Science, Vol. 296, 550-53 (2002)
/D.G./		Anna-Marija Helt and Denise A. Galloway, *Mechnisms by which DNA tumor oncoproteins target the Rb family of pocket proteins*, Carcinogenesis, Vol. 24 No. 2, 159-69 (2003)
/D.G./		Sathyamangalam Swaminathan and BayarThimmapaya, *Transactivation of Adenovirus E2-early Promoter by E1A and E4 6/7 in the Context of Viral Chromosome*, J. Molecular Biology, Vol. 258, 736-46 (1996)
/D.G./		Wilma T. Steegenga, et al., *The large E1B protein together with the E4orf6 protein target p53 for active degredation in adenovirus infected cells,* Oncogene, Vol. 16, 349-57 (1998)
/D.G./		David A. Ornelles and Thomas Shenk, *Localization of the Adenovirus Early Region 1B 55-Kilodalton Protein during Lytic Infection: Association with Nuclear Viral Inclusions Requires the Early Region 4 34-Kilodalton Protein,* J. of Virology, 424-39 (Jan. 1991)
/D.G./		Marshall S. Horwitz, *Adenovirus Immunoregulatory Genes and Their Cellular Target,* Virology, Vol. 279, 1-8 (2001)
/D.G./		Ann E.Tollefson et al., *The Adenovirus Death Protein (E3-11.6K) Is Required at Very Late Stages of Infection for Efficient Cell Lysis and Release of Adenovirus from Infected Cells*, J. of Virology ,Vol. 70, 2296-2306 (Apr. 1996)
/D.G./		Konstantin Doronin et al., *Tumor-Specific, Replication-Competent Adenovirus Vectors Overexpressing the Adenovirus Death Protein,* J. of Virology, Vol. 74 No.13, 6147-55 (2000)
/D.G./		Pierre A. Boulanger and Eric G. Blair, *Expression and interactions of human adenovirus oncoproteins*, Biochemistry J.Vol. 275, 281-99 (1991)
/D.G./		Silke Weigel and Matthias Dobbelstein, *The Nuclear Export Signal within the E4orf6 Protein of Adenovirus Type 5 Supports Virus Replication and Cytoplasmic Accumulation Of Viral mRNA*, J. of Virology, Vol. 74 No. 2, 764-72 (Jan. 2000)
/D.G./		Keith N. Leppard, *Regulated RNA Processing and RNA Transport during Adenovirus Infection,* Seminars in Virology, Vol. 8, 301-07 (1998)

/D.G./		Okamoto et al., *Direct interaction of p53 with the Y-box binding protein, YB-1: a mechanism for regulation of human gene expression,* Oncogene, Vol. 19, 6194-292 (2000)
/D.G./		Peter R. Mertens et al., *Glomerular Mesangial Cell-specific Transactivation of Matrix Metalloproteinase 2 Transcription Is Mediated by YB-1*, J. of Biological Chemistry, Vol. 272 No. 36., 22905-12 (1997)
/D.G./		Peter R. Mertens et al., *Glomerular Mesangial Cell-specific Transactivation of Matrix Metalloproteinase 2 Transcription Is Mediated by YB-1*, J. of Biological Chemistry, Vol. 272 No. 36., 22905-12 (1997)
/D.G./		Ching-Yi Chen et al., *Nucleolin and YB-1 are required for JNK-mediated interleukin-2 mRNA stabilization during T-cell activation*, Genes & Development, Vol.14, 1236-48 (2000)
/D.G./		Takefumi Ohga, et al., *Role of the Human Y Box-binding Protein YB-1 in Cellular Sensitivity to the DNA-damaging Agents Cisplatin, Mitomycin C, and Ultraviolet Light,* Cancer Research ,Vol 56, 4224-28 (Sept. 1996)
/D.G./		Hiroto Izumi et al., *Y box-binding protein-1 binds preferentially to single-stranded nucleic acids and exhibits 3'-5' exonuclease activity,* Nucleic Acid Research, Vol. 29 No. 5, 1200 – 07 (2001)
/D.G./		Tomoko Ise et al., *Transcription Factor Y-Box Bindings Protein 1 Binds Preferentially to Cisplatin-modified DNA and Interacts with Proliferating Cell Nuclear Antigen*, Cancer Research, 342-6 (Jan. 1999)
/D.G./		Per S. Holm et al.*YB-1 Relocates to the Nucleus in Adenovirus-infected Cells and Facilitates Viral Replication by Inducing E2 Gene Expression through the E2 Late Promoter* J. of Biological Chemistry, Vol. 277 No. 12, 10427-34 (Mar. 2002)
/D.G./		Felicia D. Goodrum and David A. Ornelies, *Roles for the E4 orf6, orf3, and E1B 55-Kilodalton Proteins in Cell Cycle-Independent Adenovirus Replication*, J. of Virology, Vol. 73 No. 9, 7474-88 (Sept.1999)
/D.G./		Karsten Jurchott et al., *YB-1 as a Cell Cycle-regulated Transcription Factor Facilitating Cyclin A and Cyclin B1 Gene Expression,* J. of Biological Chemistry, Vol. 278 No. 30, 270988-96 (2003)
/D.G./		Takefumi Ohga et al., *Direct Involvement of the Y-box Binding Protein YB-1 in Gentoxic Stress-induced Activation of the Human Multidrug Resistance 1 Gene*, J. of Biological Chemistry, 5997-6000 (1998)
/D.G./		Yoshinari Makino et al., *Structural and functional analysis of the human Y-box binding protein (YB-1) gene promoter*, Nucleic Acids Research, Vol. 24 No. 10, 1873-78 (1996)
/D.G./		Injae Chung et al., *Use of L-plastin promoter to develop an adenoviral system that confers transgene expression in ovarian cancer cells but not in normal mesothelial cells,* Cancer Gene Therapy, Vol. 6 No. 2, 99-106 (1999)
/D.G./		Jane Zhang et al., *Identification of Human Uroplakin II Promoter and Its Use in the Construction of CD8840, a Urothelium-specific Adenovirus Variant That Eliminates Established Bladder Tumors in Combination with Docetaxel,* Cancer Research, Vol. 62, 3743-50 (July 2002)

/D.G./		Ilana Branstein et al., *Human Telomerase Reverse Transcriptase Promoter Regulation in Normal and Malignant,* Cancer Research, Vol. 61, 5529-36 (July 2001)
/D.G./		AS Majumdar, *The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy wile preventing hepatotoxicity encountered with constitutive promoters,* Gene Therapy, Vol. 8, 568-78 (2001)
/D.G./		Victor V. Levenson (Chernokhvostov), *Pleiotropic Resistance to DNA-interactive Drugs Is Associated with Increased Expression of Genes,* Cancer Research, Vol. 60, 5027-30, (Sept. 2000)
/D.G./		Yoshinao Oda et al., *Nuclear Expression of YB-1 Protein Correlates with P-Glycoprotein Expression in Human Osteosarcoma,* Clinical Cancer Research, 2273-77 (Sept. 1998)
/D.G./		Thorsten Stiewe et al., *Inactivation of Reintoblastoma (RB) Tumor Suppressor by oncogenic Isoforms of the p53 Family member p73,* J. of Biological Chemistry, 14230-36 (2003)
/D.G./		Stuart A. Nicklin et al., *Ablating Adenovirus Type 5 Fiber-CAR binding and HI Loop Insertion of the SIGYPLP Peptide Generate an Endothelial Cell-Selective Adenovirus,* Molecular Therapy, Vol. 4 No. 6, 534-42 (Dec. 2001)
EXAMINER /David Guzo/	**DATE CONSIDERED**	01/12/2009